Driving Change: What the PCC Working Group Has Learned and What’s Next
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to inform pathway developers and practices about a greater span of costs than simply drug costs; provide relevant context in competitive situations; and identify areas for quality improvement, efficiency. In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care costs—including administration, supportive medications, labs, imaging, and adverse event management—highlighting its adaptability across diseases and stakeholders, and its potential to drive transparency, value-based contracting, and data-driven decision-making at the point of care.
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Journal of Clinical Pathways or HMP Global, their employees, and affiliates.
